Current modalities of sickle cell disease management

Abstract Sickle cell disease (SCD) affects nearly 100,000 people in the United States of America and the sickle gene is present in approximately 8% of black Americans. Among Africans, the prevalence of sickle cell trait (heterozygosity) is as high as 30%. While SCD occurs among varying racial and ethnic groups, it is more commonly prevalent in individuals of African or African-American descent. This inherited blood disorder causes varying symptoms and complications among affected children and adults and early diagnosis and treatment are essential to help reduce mortality rates. Because there is no cure for SCD, management is vital to survival. Hence, there are different approaches in use to aid those living with SCD; thus, this paper provides insight into the current methods that are implemented in the management and maintenance of this disease.

[1]  S. Thein,et al.  Recent Advances in the Treatment of Sickle Cell Disease , 2020, Frontiers in Physiology.

[2]  T. Williams,et al.  Sickle Cell Anemia and Its Phenotypes. , 2018, Annual review of genomics and human genetics.

[3]  C. Rotimi,et al.  Whole-Genome-Sequence-Based Haplotypes Reveal Single Origin of the Sickle Allele during the Holocene Wet Phase , 2017, bioRxiv.

[4]  Michael L Kaufman,et al.  b-globin gene transfer to human bone marrow for sickle cell disease , 2018 .

[5]  P. Adams-Graves,et al.  Recent treatment guidelines for managing adult patients with sickle cell disease: challenges in access to care, social issues, and adherence , 2016, Expert review of hematology.

[6]  K. Gammon.  Gene therapy: Editorial control , 2014, Nature.

[7]  George M Whitesides,et al.  Density-based separation in multiphase systems provides a simple method to identify sickle cell disease , 2014, Proceedings of the National Academy of Sciences.

[8]  S. Sweitzer,et al.  Evidence for the endothelin system as an emerging therapeutic target for the treatment of chronic pain , 2014, Journal of pain research.

[9]  J. Powell,et al.  Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. , 2014, JAMA.

[10]  A. Sanyaolu,et al.  Evaluating the knowledge of sickle cell disease and hemoglobin electrophoretic pattern among people living in Sekondi-Takoradi Metropolis, Ghana , 2014 .

[11]  D. Rees,et al.  The spleen and sickle cell disease: the sick(led) spleen , 2014, British journal of haematology.

[12]  S. Chou.  Transfusion therapy for sickle cell disease: a balancing act. , 2013, Hematology. American Society of Hematology. Education Program.

[13]  R. Kruse-Jarres,et al.  Management of sickle cell disease from childhood through adulthood. , 2013, Blood reviews.

[14]  Michael L Kaufman,et al.  β-globin gene transfer to human bone marrow for sickle cell disease. , 2013, The Journal of clinical investigation.

[15]  D. Hamer,et al.  Systematic review of current and emerging strategies for reducing morbidity from malaria in sickle cell disease , 2013, Tropical medicine & international health : TM & IH.

[16]  N. Imaga.  Phytomedicines and Nutraceuticals: Alternative Therapeutics for Sickle Cell Anemia , 2013, TheScientificWorldJournal.

[17]  G. Serjeant.  The natural history of sickle cell disease. , 1982, Cold Spring Harbor perspectives in medicine.

[18]  J. Old.  CONVENTIONAL PRENATAL DIAGNOSIS , 2013 .

[19]  S. Shurin,et al.  Future directions of sickle cell disease research: The NIH perspective , 2012, Pediatric blood & cancer.

[20]  N. Aronson,et al.  Future Research Needs for Hematopoietic Stem-Cell Transplantation in the Pediatric Population , 2012 .

[21]  J. Orak,et al.  Masked hypertension is prevalent in children with sickle cell disease: a Midwest Pediatric Nephrology Consortium study , 2012, Pediatric Nephrology.

[22]  Thomas N. Williams,et al.  Sickle Cell Disease in Africa , 2011, American journal of preventive medicine.

[23]  C. J. Wang,et al.  Management of Children With Sickle Cell Disease: A Comprehensive Review of the Literature , 2011, Pediatrics.

[24]  J. Glassberg.  Evidence-based management of sickle cell disease in the emergency department. , 2011, Emergency medicine practice.

[25]  W. Jastaniah.  Epidemiology of sickle cell disease in Saudi Arabia , 2011, Annals of Saudi medicine.

[26]  M. Gladwin,et al.  Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. , 2011, JAMA.

[27]  K. Yeom,et al.  Effect of chronic red cell transfusion therapy on vasculopathies and silent infarcts in patients with sickle cell disease , 2011, American journal of hematology.

[28]  R. Zimmerman,et al.  Sickle Cell Disease and Transcranial Doppler Imaging: Inter-Hemispheric Differences in Blood Flow Doppler Parameters , 2011, Stroke.

[29]  A. Al-Salem,et al.  Splenic Complications of Sickle Cell Anemia and the Role of Splenectomy , 2010, ISRN hematology.

[30]  Wally R. Smith,et al.  Sickle-cell pain: advances in epidemiology and etiology. , 2010, Hematology. American Society of Hematology. Education Program.

[31]  K. Hassell.  Population estimates of sickle cell disease in the U.S. , 2010, American journal of preventive medicine.

[32]  S. Obaro,et al.  Infection in sickle cell disease: a review. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[33]  M. Buchowski,et al.  Growth patterns in children with sickle cell anemia during puberty , 2009, Pediatric blood & cancer.

[34]  S. Roseff.  Sickle cell disease: a review , 2009, Immunohematology.

[35]  M. Goossens,et al.  Neonatal screening for sickle cell disease in France , 2008, Journal of Clinical Pathology.

[36]  U. A. Ndefo,et al.  Pharmacological management of sickle cell disease. , 2008, P & T : a peer-reviewed journal for formulary management.

[37]  M. Telen,et al.  Adhesion molecules and hydroxyurea in the pathophysiology of sickle cell disease , 2008, Haematologica.

[38]  A. James,et al.  Morbidity associated with sickle cell disease in pregnancy. , 2006, American journal of obstetrics and gynecology.

[39]  Andrew Collier,et al.  Role of transcranial Doppler ultrasonography in stroke , 2007, Postgraduate Medical Journal.

[40]  E. Vichinsky,et al.  Managing sickle cell disease , 2003, BMJ : British Medical Journal.

[41]  J. Elion,et al.  Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells , 2003, The Pharmacogenomics Journal.

[42]  K. Anie,et al.  Psychological therapies for sickle cell disease and pain. , 2002, The Cochrane database of systematic reviews.

[43]  E. Danish.  Book Review: Impact of Bone Marrow Transplantation for Symptomatic Sickle Cell Disease: An Interim Report , 2000 .

[44]  T. Higgins,et al.  Laboratory investigation of hemoglobinopathies and thalassemias: review and update. , 2000, Clinical chemistry.

[45]  C. Dezateux,et al.  Neonatal screening for sickle cell disease. , 2000, The Cochrane database of systematic reviews.

[46]  M. Nahata,et al.  Duration of Penicillin Prophylaxis in Sickle Cell Anemia: Issues and Controversies , 2000, Pharmacotherapy.

[47]  Graham R Serjeant,et al.  Sickle-cell disease , 1984, The Lancet.

[48]  Scott T. Miller,et al.  Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II. , 1995, The Journal of pediatrics.

[49]  F. Konotey-Ahulu.  Penicillin prophylaxis in children with sickle cell disease. , 1991, BMJ.

[50]  E Vichinsky,et al.  Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. , 1986, The New England journal of medicine.